Laure Blouin
About
In The Last Decade
Laure Blouin
15 papers receiving 645 citations
Hit Papers
Peers
Comparison fields: 5 of 56
- Molecular Biology 446
- Cellular and Molecular Neuroscience 319
- Ophthalmology 139
- Genetics 88
- Biomedical Engineering 68
Countries citing papers authored by Laure Blouin
This map shows the geographic impact of Laure Blouin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laure Blouin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laure Blouin more than expected).
Fields of papers citing papers by Laure Blouin
This network shows the impact of papers produced by Laure Blouin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laure Blouin. The network helps show where Laure Blouin may publish in the future.
Co-authorship network of co-authors of Laure Blouin
This figure shows the co-authorship network connecting the top 25 collaborators of Laure Blouin. A scholar is included among the top collaborators of Laure Blouin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laure Blouin. Laure Blouin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 2 | |
| 3 | 4 | |
| 4 | 4 | |
| 5 | Evaluation of the efficacy of rAAV2/2-ND4 gene therapy for Leber hereditary optic neuropathy compared with the natural history | 1 |
| 6 | Partial recovery of visual function in a blind patient after optogenetic therapy breakdown → | 424 |
| 7 | 1 | |
| 8 | 1 | |
| 9 | 19 | |
| 10 | Optogenetic GS030 Therapy in Subjects with Retinitis Pigmentosa: Safety and Tolerability Up to Two Years After Treatment Administration in the Phase 1/2a PIONEER Study | 4 |
| 11 | Optogenetics in the Clinic: PIONEER, a Phase 1/2a Gene Therapy Program for Non-Syndromic Retinitis Pigmentosa | 2 |
| 12 | 43 | |
| 13 | Bilateral Visual Improvement with Unilateral Gene Therapy for Leber Hereditary Optic Neuropathy (LHON) | 2 |
| 14 | 6 | |
| 15 | rAAV2/2-ND4 for the Treatment of Leber Hereditary Optic Neuropathy (LHON): 72-Week Data from the REVERSE Phase III Clinical Trial | 2 |
| 16 | 82 | |
| 17 | 69 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.